Proanthocyanidin enhances the antitumor efficacy of doxorubicin and reverses drug resistance in preclinical models, partially by promoting apoptosis and increasing intracellular doxorubicin accumulation.
Authors
No takes yet. Share an insight, caveat, or question.
Should not change doxorubicin use; hypothesis-generating for proanthocyanidin adjunct in resistant tumors pending human trials.
Zhang et al. (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: